Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
Source: SeekingAlpha
2026-04-15 16:07:01 ET
The last time I spoke about Biohaven Ltd. ( BHVN ) it was with a Seeking Alpha article entitled " Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025 ." With respect to this article, I mentioned that the company was approaching its review by the FDA of its drug troriluzole for the treatment of patients with Spinocerebellar Ataxia [SCA]. I had a Strong Buy on this stock the last time around based on this key event....
Read the full article on Seeking Alpha
For further details see:
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
Eli Lilly and Company
NASDAQ: LLY
LLY Trading
1.0% G/L:
$1147.79 Last:
2,429,032 Volume:
$1143.38 Open:
LLY Latest News
June 06, 2026 12:35:00 pm
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
LLY Stock Data
$977,526,804,738
935,929,919
9.81%
2658
N/A
Pharmaceuticals
Healthcare
US
Indianapolis
